Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
José Luis Venegas-RodríguezInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Jesús Arturo Hernández-SandovalInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Melva Gutiérrez-AnguloInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-3848-8892
José Miguel Moreno-OrtizInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-7555-9851
Anahí González-MercadoInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-8005-1304
Jorge Peregrina-SandovalDepartamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Zapopan 44600, Jalisco, Mexico.
Helen Haydee Fernanda Ramírez-PlascenciaFacultad de Medicina, Decanato de Ciencia de la Salud, Universidad Autónoma de Guadalajara, Zapopan 45129, Jalisco, Mexico.
Beatriz Armida Flores-LópezDepartamento de Ciclo de Vida, Facultad de Medicina, Universidad Autónoma de Guadalajara, Zapopan 45129, Jalisco, Mexico.ORCID 0000-0003-1965-7654
Carlos Rogelio Alvizo-RodríguezFacultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla 72420, Puebla, Mexico.ORCID 0000-0002-9050-9606
Jesús Alonso Valenzuela-PérezServicio de Colon y Recto, Hospital Civil "Dr. Juan I. Menchaca", Guadalajara 44340, Jalisco, Mexico.
Sergio Cervantes-OrtizServicio de Colon y Recto, Hospital Civil "Dr. Juan I. Menchaca", Guadalajara 44340, Jalisco, Mexico.
María de la Luz Ayala-MadrigalInstituto de Genética Humana "Dr. Enrique Corona Rivera", Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-8875-5624
Funding
University of Guadalajara Fondos CUCS para proyectos de Impulso a la Investigación (PIN 2021-II)
6 · The paper itself
Abstract
We searched for the prevalence of actionable somatic mutations in exon 2 of the
Indexed as
colorectal cancerexon 2 mutationKRAS geneLatin American genetic variations
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.